- Chinese Death Star: The moon cited as the perfect launch pad for ballistic missiles
- Help wanted: Homeland Security plagued by vacancies at the top
- We are not amused: Queen’s protection officers warned to keep ‘sticky fingers’ off the royal cashews
- Unleash the crossbows: Gov. Scott Walker creates new hunting season
- Bubonic plague kills 20 in Madagascar
- G-20 diplomats fell for hacker attack promising nude photos of former French first lady Carla Bruni
- Minnesota guardsman charged with stealing private soldier data for fake IDs
- Florida appeals court rules universities can’t regulate guns
- Vladimir Putin defends Russian conservative values
- Tea Party Patriots call key GOP firing a declaration of war
Shire will pull blood-pressure drug cited by FDA
Question of the Day
WASHINGTON (AP) - Shire PLC said Tuesday it will pull a blood-pressure drug off the market following warnings from federal regulators who said the drug has not been proven effective.
The Irish drugmaker said in a statement it will withdraw ProAmatine by the end of September. The announcement came one day after the Food and Drug Administration threatened to pull the drug because of missing data on its effectiveness.
The FDA approved ProAmatine in 1996 based on promising early results in treating low blood pressure. But the FDA said Shire never established the long-term benefits of the drug, as required under the agency’s so-called accelerated approval system.
The company also said it notified the FDA and physicians last year that it would pull the drug from the market effective Sept. 30.
On Monday the FDA issued a letter to Shire and several drugmakers that market generic versions of ProAmatine, proposing a withdrawal of the drug from the market. FDA spokespeople said the letter marked the first time the agency threatened to pull a drug off the market due to missing follow-up data, though it has long held that power.
Generic manufacturers of the drug include Mylan Pharmaceuticals and Sandoz Inc. Those generic products would also be subject to a market withdrawal, unless their manufacturers complete the studies requested by the FDA.
Roughly 100,000 U.S. patients received prescriptions for ProAmatine or generic versions last year, according to the FDA. The drug is approved to treat orthostatic hypotension, a type of low blood pressure that causes patients to become dizzy or faint when standing upright.
Shares of Shire PLC fell 17 cents Tuesday to $68.84 in afternoon trading.
By Matt Kibbe
The short-term deal will assure long-term overspending
- Obama's Afghanistan experts stumped on U.S. death toll, war costs during hearing
- Comma on!: Twitter erupts over Obama-Castro 'marriage'
- NAPOLITANO: A conspiracy so vast
- All-out war breaks out in GOP over budget pact
- White House faces press revolt over access to Obama's South Africa flight
- MALCOLM/REIMER: Over-criminalization undermines respect for legal system
- GOP Rep. Tim Murphy rolls out mental health legislation
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
- Selfie at heart of Obama fiasco to stay secret
- Biden guarantees victory on immigration reform
Independent voices from the The Washington Times Communities
Chef Mary Moran discusses the food we eat, where it comes from and what it does for us.
An informed and often humorous take on the world of advertising, public relations and social media. 100% Pure. Not from concentrate.
Does it take over 25 years in public service to really know what goes on in Washington?
NFL junkie Eric Golub reports on his favorite obsession. There is no football offseason. Every February he pretends to care about other sports while sobbing uncontrollably each Sunday until September.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow